Have found following information on USFDA site, wherein some one is asking for copy of Form483 for supriya’s USFDA inspection carried out on 6th Feb 2026. Form 483 means there is some issue. But not sure whether person asking is sure about there is Form 483 involved. But its seems there was inspection done, but interview date is of Jan 2026 and inspection date from below seems to be Feb 2026.
FDA-FOIA-2026-1475
12-02-2026
Deepak Gupta
Hi, I hereby request you to share the Form 483 for the Inspection of Supriya Lifescience Limited. The site is Located at Lote Parshuram Industrial Area, M.I.D.C, Tal Khed, Dist Ratnagiri, India. The FEI is 3007497376. The Inspection ended on 6th February 2026.
Very good results. PAT Crossed 200 Cr. Company able to maintain Margin above 30% also increase the top line in decent phase with internal accruals and zero debt with very good ROE. Hope this may continue
Has anyone done a deep dive into the reasons behind such high operating margins? Is it structural, or is it due to a supply–demand mismatch? Are any other global or domestic players in the same API business also able to earn this kind of margin?
High margins could be because of their strategy of backward integration to become the lowest cost producer in their chosen molecules leading to high market share.
Yes Divis also has a similar strategy and similar margin profile.
Divis lab also has CDMO which is currently more than 50% of revenue. While they do not disclose separate EBITDA margin of generics and CDMO they have acknowledged pricing pressure on generic portfolio.
